Imaging and blood tests for advanced lobular breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how well imaging scans and blood tests can show where invasive lobular breast cancer has spread in the body. It may help doctors better understand and monitor this type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage IV invasive lobular breast cancer (either new or after earlier treatment).
- Your cancer is hormone receptor positive and HER2 negative.
- You are about to start your first treatment for the metastatic cancer.
- You are able to have MRI scans and are not claustrophobic.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new blood test that looks for cancer DNA to track how lobular breast cancer responds to treatment. It is for people whose cancer has spread and who have not yet started treatment for the spread.
This trial tests a new imaging agent, [68Ga]Ga DOTA-5G, to see if it can better detect invasive lobular breast cancer that has spread to other parts of the body. It involves a PET/CT scan and may help doctors understand the extent of your cancer.
This study looks at a rare type of breast cancer called invasive lobular carcinoma that has low or no hormone receptors. The goal is to learn more about how this cancer behaves, which may help improve future treatments.
This study collects health information from adults with invasive lobular breast cancer that has spread (metastatic) to help researchers understand factors linked to survival. Joining may help build better knowledge for future treatments and care planning.
This trial is testing a new way to use MRI scans to find breast cancer that has spread to other parts of the body early. It is for people who have had aggressive breast cancer (HER2 positive or triple negative) and finished treatment with surgery, but still have a higher risk of the cancer coming back.
This trial tests a drug called ivonescimab for people with a specific type of breast cancer called invasive lobular carcinoma that has spread and is no longer responding to hormone therapy or is triple-negative. The goal is to see if it can shrink or slow the cancer.
Hear when a new Invasive Lobular Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.